Insmed (INSM) Competitors

In the previous week, Insmed had 14 more articles in the media than argenex. MarketBeat recorded 23 mentions for Insmed and 9 mentions for argenex. argenex's average media sentiment score of 0.84 beat Insmed's score of 0.70 indicating that argenex is being referred to more favorably in the media.

argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity.

argenex presently has a consensus target price of $1,056.89, indicating a potential upside of 21.83%. Insmed has a consensus target price of $205.70, indicating a potential upside of 52.27%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than argenex.

60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Insmed has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Revolution Medicines has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

94.3% of Revolution Medicines shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Insmed had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 23 mentions for Insmed and 20 mentions for Revolution Medicines. Insmed's average media sentiment score of 0.70 beat Revolution Medicines' score of 0.53 indicating that Insmed is being referred to more favorably in the media.

Insmed presently has a consensus price target of $205.70, suggesting a potential upside of 52.27%. Revolution Medicines has a consensus price target of $160.68, suggesting a potential downside of 21.27%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Revolution Medicines.

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Revolution Medicines' return on equity of -88.20% beat Insmed's return on equity.

Insmed currently has a consensus target price of $205.70, indicating a potential upside of 52.27%. Natera has a consensus target price of $301.90, indicating a potential downside of 5.89%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Natera.

Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

99.9% of Natera shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Natera had 13 more articles in the media than Insmed. MarketBeat recorded 36 mentions for Natera and 23 mentions for Insmed. Insmed's average media sentiment score of 0.70 beat Natera's score of 0.61 indicating that Insmed is being referred to more favorably in the media.

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.82% beat Insmed's return on equity.

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Biogen has a net margin of 8.32% compared to Insmed's net margin of -76.94%. Biogen's return on equity of 11.18% beat Insmed's return on equity.

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Biogen currently has a consensus target price of $224.61, suggesting a potential upside of 8.41%. Insmed has a consensus target price of $205.70, suggesting a potential upside of 52.27%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Biogen.

Biogen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

In the previous week, Insmed had 9 more articles in the media than Biogen. MarketBeat recorded 23 mentions for Insmed and 14 mentions for Biogen. Biogen's average media sentiment score of 0.94 beat Insmed's score of 0.70 indicating that Biogen is being referred to more favorably in the media.

87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.